Penicillins, Meropenem Supplier China

1938

In 1938, Jizhong Military Region Sanitary Materials Factory, the predecessor of CSPC, was established.

1994

In 1994, China Pharmaceutical Group Limited (1093.HK, the former name of the listed company) was listed in Hong Kong.

1997

In 1997, four pharmaceutical companies in Shijiazhuang merged to form CSPC .

1999

In 1999, CSPC Postdoctoral Programme Workstation was established.

2001

In 2001, Enzyme 7 - ACA was put into production, consolidating CSPC's leading position in the antibiotic market.

2002

In 2002, "Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd." was reorganized to achieve the strategic transformation from APIs-focus to preparation-focus.

2004

In 2004, the national Class I new drug NBP was launched in the Great Hall of the People.

2005

In 2005, CSPC was awarded the National Enterprise Technology Center, boasting industry-leading R&D capabilities.

2005

In 2005, a COS certificate from EDQM was awarded to our caffeine products.

2006

In 2006, a COS certificate was awarded by EDQM for our VC series of products, making CSPC the first VC manufacturer in China.

2007

In 2007, Tramadol Hydrochloride passed the EU certification, achieving a zero breakthrough in the EU certification of preparation products.

2008

In 2008, Weisheng Pharmaceutical (Shijiazhuang) Co. Ltd. became the first VC company in China to pass the EU GMP certification.

2010

In 2010, the Ministry of Science and Technology of the People’s Republic of China officially approved the establishment of the "State Key Laboratory of Drug Preparation and Drug Release Technology" by the Group.

2010

In 2010, Ouyi Pharmaceutical Co. Ltd. became the first dynamic manufacturing preparation company in China to pass the FDA on-site inspection with zero defects.

2010

In 2010, CSPC was awarded the title of "National Innovative Enterprise" by the Ministry of Science and Technology.

2010

In 2010, the project "Butylphthalide Raw Materials and Soft Capsules" won the second prize in the National Science and Technology Progress Award.

2011

In 2011, the "Butylphthalide Soft Capsule and Its Preparation Process" patent won the "China Patent Gold Award".

2011

In 2011, the State Key Laboratory of New Pharmaceutical Preparations and Excipients and the Central Pharmaceutical Research Institute of CSPC Group were opened.

2012

In 2012, Jinyouli and Duomeisu were launched, marking the beginning of the development of CSPC’s oncology drug business.

2012

In 2012, the project "Levoamlodipine Maleate Raw Materials, Preparations and Industrial Application" won the second prize in the National Technology Invention Award.

2013

In 2013, China Pharmaceutical Group Limited changed its name to CSPC Pharmaceutical Group Limited, and successfully completed its industrial restructuring.

2014

In 2014, the NBP project was awarded the "China Industry Award".

2016

In 2016, CSPC signed 3 overseas product technology licensing and commercialization cooperation agreements for high-end generic drugs with Teva, Citron, and Casper respectively.

2017

In 2017, Jinyouli won the "China Patent Gold Award".

2018

In 2018, CSPC became the first pharmaceutical constituent stock to be included in the Hong Kong’s Hang Seng Index.

2018

In 2018, Keaili [Paclitaxel for Injection (Albumin-bound)] was launched in the market.

2019

In 2019, Innovation (300765.SZ) was listed on the GEM Board of the Shenzhen Stock Exchange.

2019

In 2019, Xuanning passed the review of the FDA and became the first innovative drug in China to receive full approval by the United States.

2021

In 2021, CSPC was included and ranked 25th in the "The Pharma 1000: Top Global Pharmaceutical Company Report" published by Torreya.

2021

In 2021, CSPC's subsidiary NovaRock Biotherapeutics entered into a strategic cooperation and licensing agreement with Flame Biosciences for the antibody drug NBL-015, taking another critical step toward globalization.

2021

In 2021, the project on the establishment of key technology system and industrialization of site-directed PEGylation recombinant protein drugs won the second prize of the National Science and Technology Progress Award.

2022

In 2022, Duoenda (the world's first mitoxantrone liposome) and Copiktra (the first PI3K selective inhibitor in China) were launched in the market.

2022

In 2022, the Group's COVID-19 mRNA vaccine was approved for clinical trial.